

Adjuvant Treatment

GUIDELINE	DOCUMENT	ORGANISATION / COUNTRY	YEAR PUBLISHED
Bisphosphonates	Benefits of Adjuvant Bisphosphonates in Post menopausal women	UK National Breast Clinical Reference Group & UK Breast Cancer Group, UK	2016
<p>Comments:</p> <p>The UK Breast Cancer Group have produced a very helpful 2 page summary of the benefits of bisphosphonates as adjuvant treatment in breast cancer patients.</p>			
Bisphosphonates	Clinical advice to Cancer Alliances for the provision of Breast Cancer Services	Breast Cancer Clinical Expert Group, UK	2017
<p>Comments:</p> <p>The 2017 publication from the Breast Cancer Clinical Expert Group is not a guidance document per se but instead a list of best practice recommendations to commissioners and acute trusts for a modern breast service. It includes a recommendation that bisphosphonates should be offered to postmenopausal women "to reduce the risk of bone recurrence and fractures, and improve breast cancer survival"</p>			
Endocrine therapy	ABS Summary Statement: Update on optimal duration of adjuvant antihormonal therapy	Association of Breast Surgery, UK	2015
<p>Comments:</p> <p>The guidance from NICE is now dated. Updates are awaited from NICE or the UK Breast Cancer Group on current developments. In the meantime, following a review of all published data, ABS have produced a summary statement to help guide adjuvant hormonal therapy in appropriate patients.</p>			
Radiotherapy	Postoperative radiotherapy for breast cancer: UK consensus statement	Royal College of Radiologists (RCR), UK	2016
<p>Comments:</p> <p>This UK wide guidance is produced by the Clinical Oncology Group of the Royal College of Radiologists and is supported by ABS. It includes statements on axillary and internal mammary lymph node radiotherapy and adjuvant radiotherapy following breast conserving surgery.</p>			
Radiotherapy	Post-mastectomy radiotherapy	American Society for Clinical Oncology (ASCO)	2016
<p>Comments:</p> <p>ASCO have produced recommendations on the requirements for postmastectomy chest wall irradiation in patients with T1-2 tumours and 1-3 positive axillary nodes or patients with a positive sentinel node who do not undergo further axillary surgery.</p> <p>Recommendations for axillary radiotherapy in patients who have received neoadjuvant systemic treatment and for irradiation of internal mammary nodes and the supraclavicular fossa are also presented.</p> <p>ABS supports this document and its use in the context of a multidisciplinary meeting.</p>			

Adjuvant Treatment

GUIDELINE	DOCUMENT	ORGANISATION / COUNTRY	YEAR PUBLISHED
Treatment guidelines	Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat (DG10)	National Institute for Health & Care Excellence (NICE), UK	2013

Comments:

NICE have evaluated the relative benefits of Oncotype DX, Mammaprint, IHC4 and Mammostrat in guiding the use of adjuvant chemotherapy for patients with hormone receptor positive, lymph node negative, HER2 negative breast cancer.

Date:	February 2018
Version:	1

The guideline title in the document column includes a hyperlink to the relevant guideline. Please view the document on the ABS website to follow these links.